Placebo for TransCon CNP
Sponsors
Ascendis Pharma Growth Disorders A/S, Ascendis Pharma A/S, Visen Pharmaceuticals (Shanghai) Co., Ltd.
Conditions
AchondroplasiaAchondroplasia in Children and Adolescents
Phase 2
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
CompletedNCT04085523
Start: 2020-06-24End: 2024-10-01Updated: 2026-07-02
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia
CompletedNCT05246033
Start: 2022-01-05End: 2024-04-23Updated: 2026-08-10
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 years of age) with Achondroplasia followed by an Open Label Extension (OLE) period.
RecruitingCTIS2023-506091-27-00
Start: 2024-09-19Target: 51Updated: 2026-01-15
teACH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 years of age) with Achondroplasia
RecruitingCTIS2024-514208-15-00
Start: 2024-12-10Target: 20Updated: 2025-12-10
ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period
CompletedCTIS2024-515469-32-00
Start: 2023-03-02End: 2025-08-13Target: 42Updated: 2025-03-19